ArticleFrontiers in oncology2024

Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study.

Fei Qu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.